Scholars Central

Conference abstractPublished 19 Nov 2012

Rod-derived cone viability factor for treating blindness

Authors: Thierry Leveillard

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

In patients suffering from retinitis pigmentosa (RP), the most common form of inherited retinal degeneration, the vision loss develops in two successive steps: rod photo receptors loss precedes that of cones. This secondary event leads to central vision loss and potentially complete blindness. Because the cones underlie all visual functions in lighted environment, cone rescue was deemed to be a clinically relevant target. We have identified by high content screening a cDNA encoding the first 109 residues protein that was referred as Rod-derived Cone Viability Factor (RdCVF). The bifunctional Nucleoredoxin-like gene Nxnl1 encodes through alternative splicing for RdCVF, a truncated thioredoxin-like protein that is secreted from rods, and RdCVFL, a thioredoxin protein involved in redox signaling and protection against hyperoxia through its interaction with the microtubule-associated protein TAU. We evaluated the protective effects of AAV-mediated expression of these two isoforms in a recessive model of rod-cone dystrophy, the rd10 mouse. Intravenous injections of AAV-RdCVF engineered vectors slowed the rate of cone loss and increased the amplitude of the photopic electroretinogram. Expression of RdCVFL but not RdCVF reduced biproducts of oxidative stress. We also show that subretinal injection of AAV-RdCVF prevents the secondary loss of function of the cones in a dominant model of RP, the transgenic P23H rat. These results indicate distinct functions in the retina for these two Nxnl1 gene products, and suggest that RdCVF holds promise for treating retinal degenerative disease almost independently of the causative mutation.

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

Similar by topic

More from this journal

The newest in Journal of Genetic Syndromes & Gene Therapy.

All its articles

Conferences in this field

Upcoming conferences in this field.

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalJournal of Genetic Syndromes & Gene Therapy
  • SubjectGenetics & Molecular Biology
  • BylineArticles whose byline prints “Thierry Leveillard”

For authors and organisers

Publish, present and keep up with your field

Find the right journal for your paper and submit your manuscript.

Photo: Pexels